The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that’s a close cousin of ketamine, an anesthetic that’s sometimes used recreationally and often known as “Special K.” Because ketamine can cause hallucinations and out-of-body experiences, the new drug must be administered in a clinical setting. The drug is designed to start working in hours instead of weeks. It’s meant to treat people who have not found relief through other antidepressants. That’s about 5 million of the 16 million Americans with depression.
Click the audio player above to hear the full story.
Correction (March 6, 2019): A previous version of this story misspelled Spravato. The text has been corrected.
If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air. But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.
Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.
When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.